The Role of Estrogen Receptor–Targeted PET with 16α-18F-Fluoro-17β-Estradiol in Predicting Response to Endocrine Therapies in Metastatic Breast Cancer: A Metaanalysis

TL;DR

This study shows that [18F]FES PET/CT imaging can predict how well patients with metastatic breast cancer will respond to endocrine therapy by measuring estrogen receptor activity.

Contribution

The study introduces a new method using [18F]FES PET/CT imaging to predict endocrine therapy response based on lesion-level heterogeneity and SUVmax thresholds.

Findings

Patients with higher baseline SUVmean values were more likely to respond to endocrine therapy.

Lesion-level [18F]FES heterogeneity was strongly associated with shorter progression-free survival.

An SUVmax threshold of 1.8 was more effective in predicting outcomes than higher thresholds.

Abstract

[18F]16α-fluoro-17β-fluoroestradiol ([18F]FES) PET/CT imaging enables whole-body assessment of functional estrogen receptor (ER) expression in metastatic breast cancer (mBC). Identifying imaging biomarkers that predict endocrine therapy (ET) response remains a critical need in optimizing treatment selection. Our objective was to assess the predictive utility of [18F]FES PET/CT imaging in determining response to ET, with a focus on interlesional heterogeneity and individual patient outcomes. Methods: A systematic literature review and metaanalysis were conducted using 6 major databases through April 2024. Ten studies met inclusion criteria based on quantitative SUV reporting, use of FES PET/CT in mBC, and correlation with clinical outcomes. All patients had ER-positive mBC and received ET. Primary endpoints included progression-free survival (PFS) and response to ET. Patients were stratified by baseline [18F]FES PET/CT SUVmean or SUVmax thresholds (including 1.8) and by interlesional [18F]FES heterogeneity (presence of both [18F]FES-positive and [18F]FES-negative lesions). Results: Responders had a significantly higher baseline SUVmean than nonresponders (standardized mean difference, 0.91; 95% CI, 0.49–1.34; P < 0.001). Patients with a baseline SUVmax below 1.5 were significantly less likely to respond (odds ratio, 0.11; 95% CI, 0.02–0.72; P = 0.02). Across 5 studies, patients with heterogeneous [18F]FES uptake had a shorter median PFS (2.4–12.4 mo) than did those with all [18F]FES-positive lesions (14.6–23.6 mo), a statistically significant difference (ratio of median PFS, 0.25; 95% CI, 0.17–0.36; P < 0.001). In an individual-level analysis (n = 101), lesion-level [18F]FES-heterogeneous uptake was associated with a PFS of 5.5 versus 21.6 mo and a hazard ratio of 5.4 (95% CI, 3.2–9.4; P < 0.001). An [18F]FES SUVmax threshold of at least 1.8 was more prognostic of PFS than were higher SUVmax thresholds. Conclusion: [18F]FES PET/CT imaging provides prognostic insight beyond static ER testing by identifying functional heterogeneity in mBC. Lesion-level FES heterogeneity based on an SUVmax threshold of 1.8 may help stratify patients unlikely to benefit from ET, guiding more personalized treatment strategies.

Figures